| Literature DB >> 29928670 |
Soumita Das1, Rashini Jayaratne2, Kim E Barrett2.
Abstract
Every year, enteric infections and associated diarrhea kill millions of people. The situation is compounded by increases in the number of enteric pathogens that are acquiring resistance to antibiotics, as well as (hitherto) a relative paucity of information on host molecular targets that may contribute to diarrhea. Many forms of diarrheal disease depend on the dysregulation of intestinal ion transporters, and an associated imbalance between secretory and absorptive functions of the intestinal epithelium. A number of major transporters have been implicated in the pathogenesis of diarrheal diseases and thus an understanding of their expression, localization, and regulation after infection with various bacteria, viruses, and protozoa likely will prove critical in designing new therapies. This article surveys our understanding of transporters that are modulated by specific pathogens and the mechanism(s) involved, thereby illuminating targets that might be exploited for new therapeutic approaches.Entities:
Keywords: ATP, adenosine triphosphate; ATPase, adenosine triphosphatase; CDI, Clostridium difficile infection; CFTR, cystic fibrosis transmembrane conductance regulator; CLCA1, chloride channel accessory 1; CT, cholera toxin; CXCR2, C-X-C motif chemokine receptor 2; DRA, down-regulated in adenoma; Diarrhea; ENaC, epithelial sodium channel; EPEC, enteropathogenic Escherichia coli; ETEC, enterotoxigenic Escherichia coli; Enteric Pathogen; Epithelium; EspG, Escherichia coli secreted protein G; GPR39, G-protein coupled receptor 39; Ion Transport; KCC, potassium-chloride cotransporter; LPA, lysophosphatidic acid; LT, heat-labile toxin; NHE, sodium/hydrogen exchanger; NHERF2, sodium/hydrogen exchanger regulatory factor 2; NKCC, sodium-potassium-2 chloride cotransporter; ORT, oral rehydration therapy; PKC, protein kinase C; SGLT1, sodium-glucose cotransporter 1; SLC, solute carrier; ST, heat-stabile toxin; TNF, tumor necrosis factor; Tcd, Clostridium difficile toxin; ZnR, zinc sensing receptor; cAMP, adenosine 3′,5′-cyclic monophosphate
Year: 2018 PMID: 29928670 PMCID: PMC6007821 DOI: 10.1016/j.jcmgh.2018.02.009
Source DB: PubMed Journal: Cell Mol Gastroenterol Hepatol ISSN: 2352-345X
Major Ion Transporters Targeted by Enteric Infections
| Transport function | Transporter | Location | Examples of regulation by enteric pathogens |
|---|---|---|---|
| Absorption | NHEs | Apical membrane of small intestinal villus and surface epithelial cells in colon | Function of NHE2 and NHE3 decreased in response to cholera toxin |
| SGLT1 | Apical membrane of small intestinal villi | Function decreased by EPEC infection | |
| ENaC | Apical membrane of surface cells in distal colon | Decreased by | |
| DRA | Apical membrane of small intestinal villous cells and surface cells in colon | Decreased by EPEC, | |
| Secretion | CaCC | For CLCA1 in human beings, apical membrane of small intestinal and colonic crypt epithelial cells (and goblet cells) | Possibly stimulated by |
| NKCC1 | Basolateral membrane of small intestinal and colonic crypt epithelial cells | In cell lines and tissue ex vivo, expression increased by enteroinvasive | |
| CFTR | Apical membrane of small intestinal and colonic epithelial cells with expression decreasing from crypt to villus | Increased activity after infection with ETEC, enteroinvasive | |
| Redistributed into epithelial cytosol without a change in expression after | |||
| Absorption and secretion | Na+, K+ ATPase | Basolateral membrane of epithelial cells throughout the small intestine and colon | |
| Activated by the magnesium transporter C (MgtC) virulence factor of |
ACE, accessory cholera enterotoxin; CaCC, Ca2+-activated chloride channel; CLCA1, chloride channel accessory 1; EHEC, enterohemorrhagic E coli; Stx2, Shiga toxin 2.
Figure 1Localization of absorptive ion transporters (discussed in text) in the small intestine and colon, and their regulation by pathogens or their secreted toxins. The figure is not intended to imply that the illustrated transporters are necessarily expressed in the same cells. Note particularly that ENaC is present only in the distal colon. The red bars indicate inhibitory effects. The effect shown for Salmonella on the Na+, K+ ATPase consists of mislocalization to the apical membrane that would be expected to disrupt absorptive transport; however, note that a stimulatory effect of a Salmonella effector on the ATPase also has been reported (not shown). CT, cholera toxin; DRA, down-regulated in adenoma; ENaC, epithelial sodium channel; EPEC, enteropathogenic E. coli; KCC1, potassium chloride cotransporter-1; NHE, sodium hydrogen exchanger; NSP4, Rotavirus non-structural protein 4; SGLT1, sodium glucose cotransporter-1; ST, heat-stable toxin of E. coli; LT, heat-labile toxin of E. coli; TcdB, C. difficile toxin B.
Figure 2Chloride secretory mechanism in the small intestine and colon, and regulation of its constituent transporters by pathogens or their secreted toxins. The green arrows and red bars represent stimulatory and inhibitory effects, respectively. CaCC, calcium-activated chloride channel; ACE, accessory cholera enterotoxin; TDH, thermostable direct hemolysin of V parahemolyticus; NSP4, rotavirus nonstructural protein-4; KCNN4, calcium-activated potassium channel; KvLQT1/KCNE3, cAMP-activated potassium channel.
Examples of Therapeutics Targeting Ion Transporters That Are in Use or in Development for Infectious Diarrhea
| Treatment | Transporters | Targeted pathway | Status |
|---|---|---|---|
| Natural products: cocoa-derived flavonoids | CFTR | Flavonoids inhibit chloride secretion by blocking CFTR | Preclinical in vitro study |
| CFTR, DRA, NHE3 | LPA inhibits intestinal chloride secretion, | Preclinical in vitro studies as well as in mice with DSS colitis or treated with CT | |
| CaCC | Red wine and green tea extracts, resveratrol dimer, and tannic acid inhibit CaCC | Preclinical in vitro studies as well as a neonatal mouse model of rotaviral diarrhea | |
| NHE3 | Up-regulates NHE3 | Preclinical in vitro studies | |
| DRA | Up-regulates DRA | Preclinical in vitro studies | |
| (R)-Benzopyrimido-pyrrolo-oxazine-dione-27 | CFTR | Inhibits CFTR | Preclinical studies in mice treated with CT or ST, and in human enteroids |
| Thiazolidione, pyrimido-pyrrolo-quinoxalinedione/benzopyrimido-pyrrolo-oxazinedione, and glycine hydrides | CFTR | CFTR inhibitors | Preclinical in vitro and mouse studies |
| Crofelemer | CFTR, CaCC | Partial antagonist of CFTR, relatively strong inhibitor of CaCCs | Approved |
| Clotrimazole | KCNN4 | Blocks basolateral K+ channels, which prevents chloride secretion | Approved for antifungal use but no trials in diarrheal disease |
| Zinc | KCC1 | ZnR activation stimulates chloride absorption | Approved as supplement to ORS |
| Antisecretory factor, Salovum (AS-Faktor AB, Stockholm) | Undefined | Prevents intestinal fluid secretion induced by CT, ST, TcdA | Shown to be effective against diarrhea in small trials |
CaCC, Ca2+-activated chloride channel; DSS, dextran sulfate sodium; KCNN, calcium-activated potassium channel.